Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients.

Biomarkers Female Humans Inflammation Inflammatory Breast Neoplasms Interferon-gamma Interleukin-6 Interleukin-8 Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha

Journal

JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827

Informations de publication

Date de publication:
01 07 2022
Historique:
accepted: 18 05 2022
received: 24 02 2022
revised: 20 04 2022
pubmed: 29 7 2022
medline: 31 8 2022
entrez: 28 7 2022
Statut: ppublish

Résumé

Inflammation contributes to poor behavioral, functional, and clinical outcomes in cancer survivors. We examined whether standard cancer treatments-radiation and chemotherapy-led to acute and persistent changes in circulating markers of inflammation in breast cancer patients. A total of 192 women diagnosed with early stage breast cancer provided blood samples before and after completion of radiation and/or chemotherapy and at 6-, 12-, and 18-month posttreatment follow-ups. Samples were assayed for circulating inflammatory markers, including tumor necrosis factor-α (TNF-α) and interleukin (IL)-6, downstream markers of their activity (soluble TNF receptor type II [sTNF-RII], C reactive protein), and other inflammatory mediators (IL-8, interferon-γ [IFN-γ]). Analyses evaluated within-group changes in inflammatory markers in 4 treatment groups: no radiation or chemotherapy (n = 39), radiation only (n = 77), chemotherapy only (n = 18), and chemotherapy with radiation (n = 58). Patients treated with chemotherapy showed statistically significant increases in circulating concentrations of TNF-α, sTNF-RII, IL-6, and IFN-γ from pre- to posttreatment, with parameter estimates in standard deviation units ranging from 0.55 to 1.20. Those who received chemotherapy with radiation also showed statistically significant increases in IL-8 over this period. Statistically significant increases in TNF-α, sTNF-RII, IL-6, IFN-γ, and IL-8 persisted at 6, 12, and 18 months posttreatment among patients treated with chemotherapy and radiation (all P < .05). Patients treated with radiation only showed a statistically significant increase in IL-8 at 18 months posttreatment; no increases in any markers were observed in patients treated with surgery only. Chemotherapy is associated with acute increases in systemic inflammation that persist for months after treatment completion in patients who also receive radiation therapy. These increases may contribute to common behavioral symptoms and other comorbidities in cancer survivors.

Sections du résumé

BACKGROUND
Inflammation contributes to poor behavioral, functional, and clinical outcomes in cancer survivors. We examined whether standard cancer treatments-radiation and chemotherapy-led to acute and persistent changes in circulating markers of inflammation in breast cancer patients.
METHODS
A total of 192 women diagnosed with early stage breast cancer provided blood samples before and after completion of radiation and/or chemotherapy and at 6-, 12-, and 18-month posttreatment follow-ups. Samples were assayed for circulating inflammatory markers, including tumor necrosis factor-α (TNF-α) and interleukin (IL)-6, downstream markers of their activity (soluble TNF receptor type II [sTNF-RII], C reactive protein), and other inflammatory mediators (IL-8, interferon-γ [IFN-γ]). Analyses evaluated within-group changes in inflammatory markers in 4 treatment groups: no radiation or chemotherapy (n = 39), radiation only (n = 77), chemotherapy only (n = 18), and chemotherapy with radiation (n = 58).
RESULTS
Patients treated with chemotherapy showed statistically significant increases in circulating concentrations of TNF-α, sTNF-RII, IL-6, and IFN-γ from pre- to posttreatment, with parameter estimates in standard deviation units ranging from 0.55 to 1.20. Those who received chemotherapy with radiation also showed statistically significant increases in IL-8 over this period. Statistically significant increases in TNF-α, sTNF-RII, IL-6, IFN-γ, and IL-8 persisted at 6, 12, and 18 months posttreatment among patients treated with chemotherapy and radiation (all P < .05). Patients treated with radiation only showed a statistically significant increase in IL-8 at 18 months posttreatment; no increases in any markers were observed in patients treated with surgery only.
CONCLUSIONS
Chemotherapy is associated with acute increases in systemic inflammation that persist for months after treatment completion in patients who also receive radiation therapy. These increases may contribute to common behavioral symptoms and other comorbidities in cancer survivors.

Identifiants

DOI: 10.1093/jncics/pkac052 PMID: 35900175 PMC: PMC9420043
pubmed: 35900175
pii: 6651075
doi: 10.1093/jncics/pkac052
pmc: PMC9420043
pii:
doi:

Substances chimiques

Biomarkers 0
Interleukin-6 0
Interleukin-8 0
Receptors, Tumor Necrosis Factor 0
Tumor Necrosis Factor-alpha 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA160427
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press.

Références

Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):189-99
pubmed: 24220913
J Clin Oncol. 2018 Aug 20;36(24):2473-2482
pubmed: 29989859
J Clin Oncol. 2017 Jan 10;35(2):149-156
pubmed: 27893337
Psychosom Med. 2002 Jul-Aug;64(4):604-11
pubmed: 12140350
Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1873-83
pubmed: 24917184
Cell Death Differ. 2008 Jan;15(1):13-20
pubmed: 18007666
Semin Radiat Oncol. 2015 Jan;25(1):4-10
pubmed: 25481260
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Cancer. 2019 Feb 15;125(4):633-641
pubmed: 30561795
Brain Behav Immun. 2013 Mar;30 Suppl:S99-108
pubmed: 22884417
Cancer. 2021 Apr 15;127(8):1334-1344
pubmed: 33606273
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Brain Behav Immun. 2016 Feb;52:145-152
pubmed: 26515035
J Clin Oncol. 2011 Sep 10;29(26):3517-22
pubmed: 21825266
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):691-8
pubmed: 11597810
NPJ Breast Cancer. 2021 Jan 22;7(1):7
pubmed: 33483516
J Clin Oncol. 2015 Dec 1;33(34):4085-92
pubmed: 26527785
JNCI Cancer Spectr. 2020 May 08;4(5):pkaa037
pubmed: 33134822
J Clin Oncol. 2009 Jul 20;27(21):3437-44
pubmed: 19470939
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
J Neuroimmunol. 2016 Dec 15;301:74-82
pubmed: 27890459
J Neuroimmunol. 2018 Jan 15;314:17-23
pubmed: 29128118
Med Care. 1996 Jan;34(1):73-84
pubmed: 8551813
Brain Behav Immun. 2012 Jul;26(5):706-13
pubmed: 22406004
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Adv Exp Med Biol. 2015;862:53-75
pubmed: 26059929
Breast Cancer Res. 2019 May 28;21(1):70
pubmed: 31138314
Nat Rev Clin Oncol. 2022 Mar;19(3):173-187
pubmed: 34873313
Radiat Res. 2004 Jul;162(1):1-19
pubmed: 15222781
Annu Rev Physiol. 2013;75:685-705
pubmed: 23140366
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Cancer Discov. 2017 Feb;7(2):165-176
pubmed: 27979832
Clin Cancer Res. 2009 Sep 1;15(17):5534-40
pubmed: 19706826
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
pubmed: 18980965
Clin Cancer Res. 2014 Mar 1;20(5):1366-74
pubmed: 24423611
Brain Behav Immun. 2010 Aug;24(6):968-74
pubmed: 20353817
Nat Rev Immunol. 2018 Sep;18(9):545-558
pubmed: 29921905
Brain Behav Immun. 2012 Jul;26(5):699-705
pubmed: 22251605

Auteurs

Julienne E Bower (JE)

Department of Psychology, University of California, Los Angeles, CA, USA.
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
ORCID: 0000-0003-0813-4444

Patricia A Ganz (PA)

Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Schools of Medicine and Public Health, University of California, Los Angeles, CA, USA.

Michael R Irwin (MR)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.

Steve W Cole (SW)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Department of Medicine, University of California, Los Angeles, CA, USA.

Judith Carroll (J)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.

Kate R Kuhlman (KR)

Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Department of Psychological Science of California, University of California, Irvine, CA, USA.

Laura Petersen (L)

Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
ORCID: 0000-0002-4843-2692

Deborah Garet (D)

Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.

Arash Asher (A)

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.

Sara A Hurvitz (SA)

Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Department of Medicine, University of California, Los Angeles, CA, USA.

Catherine M Crespi (CM)

Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Department of Biostatistics, University of California, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Acute and Chronic Effects of Adjuvant Therapy...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Acute and Chronic Effects of Adjuvant Therapy...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Acute and Chronic Effects of Adjuvant Therapy...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Cancers du sein inflammatoires › Acute and Chronic Effects of Adjuvant Therapy...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Lymphokines › Facteurs d'activation des macrophages › Interféron gamma › Acute and Chronic Effects of Adjuvant Therapy...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-6 › Acute and Chronic Effects of Adjuvant Therapy...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-8 › Acute and Chronic Effects of Adjuvant Therapy...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux cytokines › Récepteurs aux facteurs de nécrose tumorale › Acute and Chronic Effects of Adjuvant Therapy...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Facteur de nécrose tumorale alpha › Acute and Chronic Effects of Adjuvant Therapy...